Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
05/09/2008
Trade Name:
OraVerse Injection 0.4 mg (0.235 mg/mL)
Generic Name or Proper Name (*):
phentolamine mesylate
Indications Studied:
Reversal of soft-tissue anesthesia, i.e., anesthesia of the lip and tongue, and the associated functional deficits resulting from an intraoral submucosal injection of a local anesthetic containing a vasoconstrictor
Label Changes Summary:
Use in children less than 6 years of age or weighing less than 15 kg (33 lbs) is not recommended Dosing information provided for children weighing 15 to 30 kg (66 lbs) Safety and efficacy were established in 2 clinical trials in children 12 to 17 years old, one trial in children ages 6 to 11 years, as well as adult studies Safety has been evaluated in pediatric patients under the age of 6 years but not efficacy Pharmacokinetics have been evaluated in children weighing 15 kg or more New indication
PREA(P):
P
Sponsor:
Novalar Pharmaceuticals, Inc.
NNPS:
FALSE'
Therapeutic Category:
Anesthetic, topical
-
-